|
注册号: Registration number: |
ChiCTR1900022891 |
|
最近更新日期: Date of Last Refreshed on: |
2019-04-30 01:47:13 |
|
注册时间: Date of Registration: |
2019-04-30 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
观察诺适得(雷珠单抗)在中国真实临床实践中的治疗模式和疗效 |
|
Public title: |
Observation for treatment Patterns and Efficacy of Lucentis (Ranibizumab) in the Real clinical Applications in China |
|
注册题目简写: |
OPERA 研究 |
|
English Acronym: |
OPERA study |
|
研究课题的正式科学名称: |
观察诺适得(雷珠单抗)在中国真实临床实践中的治疗模式和疗效 |
|
Scientific title: |
Observation for treatment patterns and efficacy with Lucentis (Ranibizumab) treatment in real life setting in approved indications in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘翠琴 |
研究负责人: |
吕林 |
|
Applicant: |
Cuiqin Liu |
Study leader: |
Lin Lv |
|
申请注册联系人电话: Applicant telephone: |
+86 021 6470 5530 |
研究负责人电话:
Study leader's |
+86 02066683995 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sci@both-win.net |
研究负责人电子邮件: Study leader's E-mail: |
lulin888@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区浦北路7号中星城602 |
研究负责人通讯地址: |
广州市先烈南路54号 |
|
Applicant address: |
Rm 602, Z Star Plaza, 7 Pubei Road, Xuhui District, Shanghai, China |
Study leader's address: |
54 Xianlie Road South, Guangzhou, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海博征商务咨询有限公司 |
||
|
Applicant's institution: |
Bothwin Pte.Ltd. |
||
|
研究负责人所在单位: |
中山大学中山眼科中心 |
||
|
Affiliation of the Leader: |
Zhongshan Ophthalmic Center, Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2018YWPJ002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学中山眼科中心 |
||
|
Name of the ethic committee: |
Zhongshan Ophthalmic Center, Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2018-07-10 00:00:00 | ||
|
伦理委员会联系人: |
颜彦杰 |
||
|
Contact Name of the ethic committee: |
Yan Yanjie |
||
|
伦理委员会联系地址: |
天河区金穗路7号珠江新城院区医疗楼1817会议室 |
||
|
Contact Address of the ethic committee: |
Room 1817, Treatment Building, 7 Jinsui Road, Tianhe District, Guangzhou, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 020 8733 2529 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学中山眼科中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongshan Ophthalmic Center, Sun Yat-sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市先烈南路54号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
54 Xianlie Road South, Guangzhou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京诺华制药有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Novartis Beijing |
||||||||||||||||||||||
|
研究疾病: |
老年黄斑病变/糖尿病视网膜水肿/视网膜血管阻塞 |
||||||||||||||||||||||
|
Target disease: |
Age-Related Macular Degeneration/Diabetic Macular Edema/Macular Edema secondary to Retinal Vein Occlusion |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
之前的干预性研究发现雷珠单抗在改善患者视力(VA)有显著的效果,然而目前尚没有真实世界研究以 评估中国临床实践中的治疗模式和有效性。 研究目的为在真实临床实践中,针对在中国已批准适应症,观察和描述接受雷珠单 抗中国患者的治疗模式和其有效性与安全性,并评估患者在24 个月内的生活质量改善。 |
||||||||||||||||||||||
|
Objectives of Study: |
Although the efficacy and safety of ranibizumab have been established in Phase 3 clinical studies, longterm safety and effectiveness in the real-world setting have not been widely documented in China. This study would allow the observation of the treatment pattern and efficacy for wet AMD (wAMD)DME and macular edema secondary to RVO patients in China in real life setting. In addition, patient management practices that could potentially serve to improve individual treatment effectiveness in real-world clinical practice have yet to be established. This data gap will be filled in by describing the Health-Related Quality of Life (HRQoL) outcomes in patients treated with ranibizumab. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
同时参与其他研究(包括任何试验药物/手术) |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Simultaneous participation in a study that includes administration of any investigation drug or procedure; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2018-10-31 00:00:00至 To 2022-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2018-10-31 00:00:00 至 To 2020-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究是基于真实世界的观察性研究,不需要随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
no randomization. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在研究完成且研究报告定稿的条件下,本非干预性研究的结果可能会被申请发表和/或 公示于可公开访问的结果数据库里。研究发表将遵守诺华内部标准和国际医学杂志编 辑委员会(ICMJE)的发表指南。临床试验公共管理平台:http://www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
http://www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
参与的研究中心将由诺华人员和/或指定的合同研究组织(CRO)启动。在研究启动 前,诺华代表(或指定人员)将与研究者和其工作人员审查方案和CRF。 研究中心将记录数据于诺华(或指定人员)提供的eCRF,诺华将提取、检查、储存和 分析该数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Participating research centers will be initiated by novartis personnel and/or designated contract research organizations (CRO). Prior to the study initiation, Novartis representatives (or designees) will review the protocol and CRF with the investigator and its staff. The research center will record the data in the eCRF provided by novartis (or designated personnel), and novartis will extract, inspect, store, monitor and analyse the data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |